FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
The FDA issued draft guidance intended to streamline the development of gene therapies by encouraging the use of existing scientific and regulatory knowledge.
Developers and manufacturers of cell and gene therapies, as well as regulatory and scientific personnel involved in bringing these products to market.
This shift suggests an FDA effort to reduce redundant data requirements by allowing developers to utilize established knowledge bases. This could potentially shorten development timelines and reduce the evidentiary burden for therapies built on known platforms or mechanisms, though the source does not detail the specific criteria for 'existing knowledge.'
Regulatory teams should review the draft guidance to identify opportunities for leveraging prior knowledge in upcoming submissions. Development teams should evaluate how existing data sets might be applied to accelerate current pipeline timelines.
The U.S. Food and Drug Administration (FDA) today issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and regulatory knowledge.
Open in openFDA / FDA.gov